A blockbuster unleashed: What happens when a big fat business explodes?

The entry of multiple Indian pharma companies into the semaglutide market signifies a major growth opportunity, potentially transforming the landscape for diabetes and weight loss treatments.

• •India is set to experience a dramatic shift as semaglutide becomes widely available.
• •Over 40 Indian companies are launching affordable generic versions.
• •This will slash prices and expand access.
• •Raises concerns about potential misuse and the need for strong oversight.
• •Risk flag: Intense price competition among generic manufacturers